Molecular Partners AG cash flow statement

In fiscal 2025, Molecular Partners AG's operations generated −$61.9m of cash; it spent $861,846 on capital projects, leaving free cash flow of −$62.7m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Molecular Partners AG: cash flow statement, annual
Fiscal year	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash from operations	−1	−31	−99	124	−66	−67	−62
Stock-based pay	2	3	4	5	6	5	5
Capital spending	1	2	1	1	1	1	1
Free cash flow	−2	−32	−101	123	−66	−68	−63
Free cash flow after stock pay	−5	−36	−105	118	−72	−73	−68
Share buybacks	—	0	0	1	0	0	—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Molecular Partners AG's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Molecular Partners AG.